TLS signs licensing contract with Stanford University
The protocol template of the Phase II trial of lisinopril is currently available on a prototype of the company’s crowdsourced web platform. The web platform allows patients, physicians,
Teva Pharmaceuticals International has made a bid to acquire a range of neuroscience assets from BioXcel Therapeutics for a total deal value of $125m.
Developed in collaboration with Genentech, BI-204 is a monoclonal antibody targeting oxidised forms of low-density lipoprotein cholesterol. In the randomized placebo controlled double-blind multicenter Phase IIa study, BI-204